These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1172 related articles for article (PubMed ID: 20137358)

  • 1. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of clinicopathology and prognosis in 181 patients with gastrointestinal stromal tumors].
    Zhang Y; Cao H; Wang M; Shen DP; Shen ZY; Ni XZ; Wu ZY; Shen YY; Liu Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Mar; 12(2):150-4. PubMed ID: 19296250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis.
    Hassan I; You YN; Shyyan R; Dozois EJ; Smyrk TC; Okuno SH; Schleck CD; Hodge DO; Donohue JH
    Ann Surg Oncol; 2008 Jan; 15(1):52-9. PubMed ID: 18000711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
    Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
    Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease.
    An JY; Choi MG; Noh JH; Sohn TS; Kang WK; Park CK; Kim S
    Eur J Surg Oncol; 2007 Oct; 33(8):1030-5. PubMed ID: 17428635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.
    Wu TJ; Lee LY; Yeh CN; Wu PY; Chao TC; Hwang TL; Jan YY; Chen MF
    BMC Gastroenterol; 2006 Oct; 6():29. PubMed ID: 17062131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An audit of surgical management of gastrointestinal stromal tumours (GIST).
    Bucher P; Egger JF; Gervaz P; Ris F; Weintraub D; Villiger P; Buhler LH; Morel P
    Eur J Surg Oncol; 2006 Apr; 32(3):310-4. PubMed ID: 16414236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.
    Rutkowski P; Wozniak A; Dębiec-Rychter M; Kąkol M; Dziewirski W; Zdzienicki M; Ptaszynski K; Jurkowska M; Limon J; Siedlecki JA
    Cancer; 2011 Nov; 117(21):4916-24. PubMed ID: 21456019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
    Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical management and clinical outcome of gastrointestinal stromal tumor of the colon and rectum.
    Chen CW; Wu CC; Hsiao CW; Fang FC; Lee TY; Che FC; Tsai WC; Jao SW
    Z Gastroenterol; 2008 Aug; 46(8):760-5. PubMed ID: 18759198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of gastrointestinal stromal tumors].
    Zhang W; Ye ZY; Shao QS; Zhao ZS; Wang YD; Xu XD
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jul; 12(4):378-81. PubMed ID: 19598024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical analysis of prognostic factors for patients with gastrointestinal stromal tumors].
    Jie ZG; Xie XP; Qin KW; Liu Y; Li ZR; Dai AB; Yao YX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2005 May; 8(3):210-2. PubMed ID: 16167229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
    Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
    Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
    Higashi D; Watanabe Y; Hirano K; Shimomura T; Egawa Y; Tomiyasu T; Ishibashi Y; Futami K; Maekawa T; Ota A; Oshige K; Iwashita A
    Anticancer Res; 2009 Nov; 29(11):4893-6. PubMed ID: 20032453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases.
    Otani Y; Furukawa T; Yoshida M; Saikawa Y; Wada N; Ueda M; Kubota T; Mukai M; Kameyama K; Sugino Y; Kumai K; Kitajima M
    Surgery; 2006 Apr; 139(4):484-92. PubMed ID: 16627057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
    Zhan WH; Wang PZ; Shao YF; Wu XT; Gu J; Li R; Wan DS; Ding KF; Shi YQ; Yu JR; Lu HS; Zou XM; Bi JW; Sun YH; Lu YF; Chen DD; Zhang XH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep; 9(5):383-7. PubMed ID: 17043955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and prognostic factors analysis in surgically resected gastrointestinal stromal tumor patients.
    Song Z; Wang JL; Pan YL; Tao DY; Gan MF; Huang KE
    Hepatogastroenterology; 2009; 56(89):149-53. PubMed ID: 19453047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.